Loading...
FATE logo

Fate Therapeutics, Inc.NasdaqGM:FATE Aktienübersicht

Marktkapitalisierung US$214.5m
Aktienkurs
US$2.10
US$5.39
61.0% unterbewertet intrinsischer Abschlag
1Y75.0%
7D10.5%
1D
Wert des Portfolios
​
Siehe

Fate Therapeutics, Inc.

NasdaqGM:FATE Lagerbericht

Marktkapitalisierung: US$214.5m

Fate Therapeutics (FATE) Aktienübersicht

Fate Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt programmierte zelluläre Immuntherapien für Krebs und Immunkrankheiten in den Vereinigten Staaten und international. Mehr Details

FATE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum2/6
Vergangene Leistung0/6
Finanzielle Gesundheit6/6
Dividenden0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 63.74%

Die Erträge sind in den letzten 5 Jahren um 9% pro Jahr gestiegen.

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 4.8% pro Jahr sinken.

Volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert


FATE Community Fair Values

Create Narrative

See what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Fate Therapeutics, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Fate Therapeutics
Historische Aktienkurse
Aktueller AktienkursUS$2.10
52-Wochen-HochUS$2.47
52-Wochen-TiefUS$0.91
Beta2.14
1 Monat Veränderung55.56%
3 Monate Veränderung43.84%
1 Jahr Veränderung75.00%
3 Jahre Veränderung-58.33%
5 Jahre Veränderung-97.25%
Veränderung seit IPO-68.28%

Aktuelle Nachrichten und Updates

Seeking Alpha • May 12

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Summary Fate Therapeutics, Inc. is downgraded from Strong Buy to Hold due to slower-than-expected clinical progress in its FT819 program for SLE. Phase 1 FT819-102 study shows promising efficacy with significant SLEDAI-2K score reductions, but patient enrollment and expansion to Regimen B remain limited. Regulatory catalysts, including potential phase 2 registration-enabling study initiation, are not expected until 2H 2026, delaying near-term value inflection. FATE maintains strong cash reserves through 2027 and has reduced operating expenses, but clinical and regulatory risks persist across its pipeline. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • May 12

Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026

Summary Fate Therapeutics, Inc. is downgraded from Strong Buy to Hold due to slower-than-expected clinical progress in its FT819 program for SLE. Phase 1 FT819-102 study shows promising efficacy with significant SLEDAI-2K score reductions, but patient enrollment and expansion to Regimen B remain limited. Regulatory catalysts, including potential phase 2 registration-enabling study initiation, are not expected until 2H 2026, delaying near-term value inflection. FATE maintains strong cash reserves through 2027 and has reduced operating expenses, but clinical and regulatory risks persist across its pipeline. Read the full article on Seeking Alpha
Analyseartikel • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyseartikel • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
Analyseartikel • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
Analyseartikel • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
Analyseartikel • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
Analyseartikel • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
Analyseartikel • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
Analyseartikel • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
Analyseartikel • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyseartikel • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
Analyseartikel • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
Analyseartikel • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Sep 22

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 30

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Summary Fate Therapeutics has potential inflection points stemming from clinical trial and regulatory momentum in the next 6-12 months. For those taking speculative positions within healthcare, this could present with potential upsides post-event(s). Those investors looking for a defensive overlay within healthcare might find weakness in FATE's measures of corporate value. With these points in mind, we rate FATE a hold with a $21 per share valuation. Investment summary There are selective opportunities located within the healthcare universe for investors taking both speculative and defensive positions. In either sense, factor rotations in H2 FY22 corroborate that value remains a thematic favorite for investors, adding a layer of resiliency to portfolios. Measures examining corporate value are therefore of upmost importance for equity investors looking ahead, in order to decipher the quality of earnings and business model one is allocating to. With this in mind, we examined Fate Therapeutics, Inc. (FATE) and found that it offers potential upsides from clinical trial and regulatory momentum over the next 6-12 months. For those on the speculative side, this is ideal. However, we also noted that for those seeking a defensive beta name in healthcare, FATE might not be the best choice, due to lack of profitability and unsupportive valuations from forward earnings. With opportunity costs front of mind, but also acknowledging the strengths in FATE's wider offering, we rate FATE a hold with a price target of $21. Exhibit 1. FATE 6-month price action Data: Refinitiv Eikon Q2 earnings indicative of regulatory, fundamental momentum Fundamental momentum is creeping up alongside regulatory momentum for FATE. Despite this, its earnings do need some cleaning up to reflect a more accurate snapshot. Revenue obtained via collaborations with Janssen and Ono Pharmaceutical (OPHLY) rose to $18.5 million in Q2 FY22, a 38% growth YoY. Meanwhile, the company saw a ~67% YoY headwind at the G&A line with expenditures increasing to $20.4 million. However, breaking down the increase in G&A, ~34% or $6.9 million ($0.07/share) was attributed to stock based compensation ("SBC"), up $4.3 million from this time last year. Operating expenses were also comprised of $81.3 million in R&D spend, that we argue should be capitalized and treated as an investment on the balance sheet [discussed later]. All in, SBC comprised $20.5 million of the $101.6 million in operating spend for the quarter. On the regulatory front, FATE achieved its first clinical milestone in its CAR T-cell product candidate, FT819. This is under an amended license agreement with Memorial Sloan Kettering Cancer Centre ("MSK"). The first milestone payment to MSK was activated following this milestone. This is important as there could be an additional 2 milestone payments obliged to MSK that are based on trading volumes of the company's stock in ranges of $100-$150/share. Changes in the fair value of these instruments is booked as income or expenditure by FATE and is therefore worth keeping an eye on from period to period and make necessary adjustments if necessary. Exhibit 2. FT819 descriptive overview Data: Fate Therapeutics Website Meanwhile, the Phase 1 trial of FATE's FY596 in combination with rituximab exhibited favorable safety data in both the single dose and dual-dose cohorts. Safety data held up well up to 900 million cells per dose, and the higher-dose regime could well be the protocol looking ahead, by estimate. From here FATA will continue to evaluate dosages for maximal therapeutic effect, with the next moves being a 3-dose cohort at a dose of 1.8 billion cells. We are intrigued to observe the outcome of the increased cellular load, particularly as the clinical protocol permits further dose escalation In terms of regulatory catalysts, investors should keep an eye out for the company's FT516 RMAT Type-B multidisciplinary meeting with the FDA this coming quarter. From here we'll have better understanding on the registrational pathways for the off-shelf programs against refractory aggressive B-cell lymphoma. Patients will include those whose disease is refractory or relapsed after previous treatment from other CD19 targeted CAR T-cell therapies. Reconciliations for accurate valuation We've identified a number of adjustments that need to be made in order to accurately value FATE, in order to understand exactly what it is we're buying. Firstly, R&D expenditure came in at $81 million for the quarter, up from $48 million YoY. We argue that R&D expenditure should be capitalized and amortized as an intangible asset, as it is an investment set to create future economic value. This has implications to earnings and investment for the company. However, we also found we can't capitalize FATE's entire R&D spend. Notably, the $33 million YoY increase in R&D stemmed from: $4.9 million increase in employee SBC expense to $13.57 million $9 million increase in spend to third-party professional consultants $8.6 million increase in expenditures for laboratory materials and supplies relating to the manufacture of product candidates and conduct of research activities. Therefore, we can only advocate to capitalize $67.4 million of R&D as an investment, seeing as SBC is an expense in our eyes. This has implications for both earnings and valuation, as discussed below. In addition, the company's drug product manufacturing facility in California has now opened with engineering runs underway. This is a tangible source of value that will supply drug products for companies conducting pivotal trials. In all, the company has $580 million in tangible book value with this included. Exhibit 3. Data & Image: HB Insights Valuation Being a clinical stage biopharma company, valuation ideally comprises a number of factors to obtain a corporate value for the company. However, we aren't confident on the predictability of estimating the prospective value of FATE's pipeline or working in terms of what's 'possible'. Instead, what's real and 'probable' are better terms to work by. With that, we observe corporate valuation in terms of earnings and investment; what's real and what's expected. We record this in shorthand with multiples of book value and earnings estimates. Instead, we are focusing on what we'd be buying today in FATE.
Seeking Alpha • Jul 28

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Needham has initiated coverage on Fate Therapeutics (NASDAQ:FATE) with a hold rating citing the potential of its stem cell cancer therapies. Fate develops induced pluripotent stem cell (iPSC) derived cancer therapeutics, primarily NK cells, which can address several challenges in cell therapy. They are off-the-shelf as opposed to current CAR-T therapies and allow for large-scale manufacturing and relatively easier genetic engineering. Analyst Gil Blum wrote, " Fate's lead programs in B-cell lymphomas and acute myeloid leukemia have potential in ~35,000 patients combined and have demonstrated promising early data. Even assuming cellular therapeutic pricing (~$300K in the US) and achievement of significant market penetration, we find FATE shares fully valued at this time." "Early POC was achieved in both BCL and AML. However, questions regarding treatment durability remain. We consider Fate's platform a compelling solution in solid tumors, despite NK iPSCs having low activity at baseline. Reports of clinical activity in solid tumors could be transformational for Fate," Blum adds. Needham's neutral rating on FATE is in line with SA Quant rating of hold. Shares dipped -5.46% to $31.36 today
Seeking Alpha • Jun 30

Fate Therapeutics names Brian Powl as chief commercial officer

Fate Therapeutics (NASDAQ:FATE) has appointed Brian Powl as its new chief commercial officer. He was most recently SVP, commercial development & marketing at MEI Pharma (MEIP). Before then, he was VP, global commercial CAR T lead at Celgene Corp.
Seeking Alpha • Jun 03

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsed/refractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022. FT516 is being explored for many other types of relapsed/refractory lymphomas besides diffuse large B-cell lymphoma. FT596 is another shot on goal in the pipeline being explored for the treatment of patients with relapsed/refractory lymphomas.

Aktionärsrenditen

FATEUS BiotechsUS Markt
7D10.5%-1.6%-0.8%
1Y75.0%34.4%27.1%

Rendite im Vergleich zur Industrie: FATE übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 34.4 erzielte.

Rendite vs. Markt: FATE übertraf den Markt US, der im vergangenen Jahr eine Rendite von 27.1 erzielte.

Preisvolatilität

Is FATE's price volatile compared to industry and market?
FATE volatility
FATE Average Weekly Movement16.1%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stabiler Aktienkurs: Der Aktienkurs von FATE war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: FATEDie wöchentliche Volatilität (16%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2007161Bob Valamehrwww.fatetherapeutics.com

Fate Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das programmierte zelluläre Immuntherapien für Krebs und Immunkrankheiten in den Vereinigten Staaten und international entwickelt. Zu den Produktkandidaten des Unternehmens mit chimären Antigenrezeptoren (CAR), die auf NK- und T-Zellen abzielen, gehören FT836, das sich in der präklinischen Phase für mehrere Tumorarten befindet, und FT522 zur Behandlung von B-Zell-Lymphomen und Autoimmunität. Zu seinen CAR-T-Zell-Programmen gehören FT819 zur Behandlung von systemischem Lupus erythematosus, FT839 zur Behandlung komplexer Autoimmunerkrankungen und FT825 zur Behandlung solider Tumore.

Fate Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Fate Therapeutics im Vergleich zum Marktanteil des Unternehmens?
FATE grundlegende Statistiken
MarktanteilUS$214.47m
Gewinn(TTM)-US$129.91m
Umsatz(TTM)US$6.32m
38.8x
Kurs-Umsatz-Verhältnis
-1.9x
Kurs-Gewinn-Verhältnis

Ist FATE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
FATE Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$6.32m
Kosten der EinnahmenUS$87.47m
Bruttogewinn-US$81.15m
Sonstige AusgabenUS$48.76m
Gewinn-US$129.91m

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-1.11
Bruttomarge-1,284.83%
Nettogewinnspanne-2,056.79%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich FATE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/21 09:49
Aktienkurs zum Tagesende2026/05/21 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Fate Therapeutics, Inc. wird von 26 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG